A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

Trial Profile

A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions
  • Acronyms MELODY-1
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 21 Nov 2015 Status changed from active, no longer recruiting to completed as per European Clinical Trials Database.
    • 17 Sep 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
    • 17 Sep 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top